Standard BioTools

Illumina

Standard BioTools Completes Sale of SomaLogic for $425 Million Amidst Financial Challenges.

Illumina's 15min chart indicates bearish MACD and KDJ signals.

StandardBioTools

Standard BioTools Completes Sale of SomaLogic to Illumina for $350M

Standard BioTools Completes SomaLogic Sale to Illumina for $350 Million in Upfront Cash

Illumina Expands Leadership in Proteomics with Completion of SomaLogic Acquisition

Catalyst<ul> <li>Recent Bullish Engulfing and MACD Death Cross signals in early January indicate favorable momentum for ILMN.</li> <li>Positive net inflow trends across all fund sizes suggest increasing institutional interest.</li> <li>Analysts rate ILMN with a mix of Strong Buy and Neutral ratings, showing institutional optimism.</li> <li>Strong fundamental factors include robust cash reserves, profitability, and asset-to-market value ratios.</li></ul>Risk<ul> <li>Technical indicators suggest a volatile market environment with no clear directional bias for ILMN.</li> <li>Analyst ratings show inconsistency, with some firms expressing caution due to valuation uncertainties.</li></ul>

Key Factors

Illumina completes acquisition of SomaLogic to expand proteomics capabilities.Standard BioTools sells SomaLogic to Illumina for $350 million in upfront cash and up to $75 million in near-term earnout payments.Illumina shares fall 3.26% in a four-day slide as technical indicators point to continued bearish momentum.

Recent Updates

ILMN News